Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolyPeptide Group AGPLYGF 61 Debt-to-EBITDA is 2.79 as of Dec. 2025, which is 310% above its 10-year median of 0.68. GuruFocus rates PLYGF with a GF Score™ of 61/100 and a GF Value™ of $40.82 (Fairly Valued). The stock has 9 warning signs investors should review. Among 690 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 79.28% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PolyPeptide Group AG's Debt-to-EBITDA or its related term are showing as below:
PLYGF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.13 Med: 0.68 Max: 4.61
Current: 4.6
During the past 8 years, the highest Debt-to-EBITDA Ratio of PolyPeptide Group AG was 4.61. The lowest was -5.13. And the median was 0.68.
PLYGF's Debt-to-EBITDA is ranked worse than 79.28% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs PLYGF: 4.60
PolyPeptide Group AG (OTCPK:PLYGF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PolyPeptide Group AG Debt-to-EBITDA Related Terms
PolyPeptide Group AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLYGF vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
PolyPeptide Group AG (PLYGF) has a Debt-to-EBITDA of 2.79 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PolyPeptide Group AG. This is 310% above median its historical median of 0.68. According to the industry distribution chart, PolyPeptide Group AG ranks #547 out of 690 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is PolyPeptide Group AG's Debt-to-EBITDA too high?
PolyPeptide Group AG's current Debt-to-EBITDA of 2.79 is 310% above median its 10-year median of 0.68. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. PolyPeptide Group AG's value of 2.79 is 66.1% above this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #547 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PolyPeptide Group AG has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #547 out of 690 companies for Debt-to-EBITDA. This places PolyPeptide Group AG in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. PolyPeptide Group AG's value of 2.79 is 66.1% above this benchmark. While the company's 10-year median is 0.68 vs. the industry median of 1.68, PolyPeptide Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current Debt-to-EBITDA of 2.79 is 66.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PolyPeptide Group AG. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current Debt-to-EBITDA is 2.79, which is 310% above median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Fairly Valued. The stock's GF Value™ is $40.82, compared to a current price of $43.00 — trading 5.3% above its estimated fair value. The current Debt-to-EBITDA is 2.79, which is 310% above median its 10-year median of 0.68 and 66.1% above the Drug Manufacturers industry median of 1.68. PolyPeptide Group AG's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Debt-to-EBITDA is 2.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $43.00 is trading 5.3% above its estimated GF Value™ of $40.82.
GuruFocus considers PolyPeptide Group AG to be Fairly Valued.
Key valuation signals for PLYGF:
Debt-to-EBITDA: 2.79 (310% above median its 10-year median of 0.68)
GF Value™: $40.82 vs. price of $43.00 (5.3% above fair value)
Industry Position: 66.1% above the Drug Manufacturers median (#547 of 690)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
61GF Score
Get the complete analysis for PLYGF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
